You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
User Adaptation of AAC Device Voices
SBC: BIOSPEECH INC Topic: NIDCDDESCRIPTION (provided by applicant): Augmentative and alternative communication devices with voice output (also known as Speech Generating Devices, or SGDs) enable individuals to speak by electronic means. Typical users of SGDs are individuals who have suffered from a stroke, traumatic brain injury, or who have neurodegenerative or neurodevelopmental disorders. In most cases, the user was able to ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Mitochondrial Dysfunction in HAART: Point of Care Tests
SBC: MITOSCIENCES, INC Topic: NIGMSDESCRIPTION (provided by applicant): Highly Active Anti-Retroviral Therapy (HAART) used to treat HIV/AIDS has serious side-effects, including metabolic complications from mitochondrial toxicities that can be life-threatening, and limit effectiveness and patient compliance. Adverse metabolic effects are now managed by adept clinicians who monitor patients closely for clinical symptoms and adjust t ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Multipurpose reversible terminators
SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC Topic: NHGRIDESCRIPTION (provided by applicant): This Phase 2 STTR application will allow the Foundation for Applied Molecular Evolution (FfAME) to complete its transfer of technology to Firebird Biomolecular Sciences LLC, allowing Firebird to commercialize nucleoside triphosphates where the 3'-OH groups are blocked by a 3'-ONH2 group. Triphosphates having this modification are accepted by DNA polymerases and ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
An Interactive Informed Consent Program for Cardiac Procedures
SBC: ARCHIE MD INC. Topic: NHLBIDESCRIPTION (provided by applicant): Informed consent has become an essential component of the doctor-patient interaction. The informed consent process requires that patients not only be given information about proposed medical treatment, but that it be presented in an understandable way so the patient can make meaningful choices about medical alternatives. At the heart of the informed consent doc ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Internet-based Fidelity Enhancement of MTFC
SBC: Tfc Consultants, Inc. Topic: NIMHDESCRIPTION (provided by applicant): The proposed project builds upon Phase I proof of concept efforts wherein the basic foundational components of an Internet-based Treatment Fidelity Monitoring System, the ITFMS, were created to assist MTFC consultants and implementing agencies to improve clinical outcomes by moving more efficiently towards and maintaining fidelity of program implementation. I ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Development of Noninvasive System for Detection of Sleep Apnea in Animals
SBC: NEOGENE BIOSCIENCES, LLC Topic: NIADESCRIPTION (provided by applicant): The long term goal of this project is to develop and commercialize noninvasive equipment, called the sleep and respiratory track (SARTrak) system, for high throughput detection of sleep apnea in animals. The specific goal for the Phase I application is to design and evaluate a basic model of the SARTrak system with eight chambers (one chamber per animal), i.e. ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
A Synthetic Human Cytomegalovirus Vaccine Platform
SBC: TOMEGAVAX, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Humanized Monoclonal Antibodies to Treat Acinetobacter Infections
SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC Topic: NIAIDDESCRIPTION (provided by applicant): In the last decade, Acinetobacter baumannii has emerged as one of the most highly antibiotic-resistant pathogens in the United States (US) and throughout the world. These infections are increasingly prevalent and highlylethal, killing 50-60% of those infected. Worse, strains of A. baumannii that no known antibiotic will kill have now emerged, and will continue ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Immunotherapeutics to prevent HCV reinfection
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Up to 170 million people worldwide are chronically infected with HCV Hepatitis C virus (HCV) putting the infected individuals at significant risk for cirrhosis, liver failure and liver cancer. End- stage liver diseasecaused by HCV is the leading indication of liver transplantation (LT) in the United States. However, reinfection with HCV occurs universally and ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Preparation and Characterization of 2nd Generation HIV-1 Maturation Inhibitor Dru
SBC: DFH Pharma, Inc Topic: NIAIDDESCRIPTION (provided by applicant): Despite advances in the development of HIV drugs there remains a need for new therapies. Toxicities associated with long term use of many of the approved HIV drugs coupled with the development of resistance drives the need for new and novel antivirals. Maturation inhibitors (MIs) represent one such class of HIV therapies. HIV maturation inhibitors block virus r ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health